XML 19 R13.htm IDEA: XBRL DOCUMENT
v3.25.2

Minority and Equity-method Investments | 6 Months Ended
--- | ---
Jun. 30, 2025
Equity Method Investments and Joint Ventures [Abstract] |
Minority and Equity-method Investments | 4. Minority and Equity-method Investments 2025 As of June 30, 2025, the aggregate amount of equity investments without readily determinable fair value using the measurement alternative is $38.7 million. During the six months ended June 30, 2025, the Company completed four minority investments. The following table reflects the consideration transferred (in millions):
Name |  | Financial Statement Classification |  | Date Acquired |  | Total Consideration |  |  | Cash Consideration |
Other minority investments |  | Other long-term assets |  | Various |  | $ | 3.9 |  |  | $ | 3.2 |
|  |  |  |  |  | $ | 3.9 |  |  | $ | 3.2 |
2024 As of December 31, 2024, the aggregate amount of equity investments without a readily determinable fair value using the measurement alternative was $35.6 million. During the year ended December 31, 2024, the Company completed several minority investments. The following table reflects the consideration transferred (in millions):
Name |  | Financial Statement Classification |  | Date Acquired |  | Total Consideration |  |  | Cash Consideration |
NovAliX |  | Other long-term assets |  | July 31, 2024 |  | $ | 50.1 |  |  | $ | 34.1 |
Other minority investments |  | Other long-term assets |  | Various |  |  | 14.2 |  |  |  | 14.2 |
|  |  |  |  |  | $ | 64.3 |  |  | $ | 48.3 |
On July 31, 2024, the Company acquired a minority equity interest in NovAliX a preclinical contract research organization specializing in expert drug discovery services, headquartered in Strasbourg, France. The Company obtained a 30% interest in NovAliX’s common stock in exchange for consideration of EUR 31.5 million (approximately $34.1 million). The Company accounts for its investment in NovAliX using the equity-method of accounting. Concurrent with the transaction, the Company entered into an agreement with the remaining shareholders that provides the Company with the right to purchase, and the shareholders with the right to sell, the remaining ownership of NovAliX for cash at a contractually defined redemption value exercisable beginning in 2029 and ending in 2034. The Company recognized a liability, classified in other long-term liabilities in the consolidated balance sheet, related to the potential obligation to acquire the remaining equity interests if the purchase option is exercised, estimated at EUR 14.4 million (approximately $16.0 million) using the discounted cash flow method. Refer to Note 11, Interest and other income (expense), net, for information on impairment charges, to write down the carrying value of certain minority investments for the three and six months ended June 30, 2025 and 2024, respectively.

X
- Definition Minority and Equity Method Investments (Text Block) + References No definition available. + Details
Name: | brkr_MinorityAndEquityMethodInvestmentsTextBlock
Namespace Prefix: | brkr_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration